.Pharmacolibrary.Drugs.ATC.R.R03AC13 .Pharmacolibrary.Drugs.ATC.R.R03AC13| name: | Formoterol |
| ATC code: | R03AC13 | route: | inhalation |
| n-compartments | 2 |
Formoterol is a long-acting beta2-adrenergic agonist (LABA) used primarily as a bronchodilator for the management of asthma and chronic obstructive pulmonary disease (COPD). It is usually administered via inhalation and is approved for use in many countries worldwide.
Pharmacokinetic parameters reported in healthy adult volunteers following single inhaled dose.
Kuna, P, et al., & Ciurlia, G (2022). Pharmacokinetics of extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide in adolescent and adult patients with asthma. Pharmacology research & perspectives 10(4) e980–None. DOI:10.1002/prp2.980 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35733414
Chen, Q, et al., & Dorinsky, P (2019). Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study. Clinical therapeutics 41(5) 897–909.e1. DOI:10.1016/j.clinthera.2019.03.007 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30982547
Soulele, K, et al., & Karalis, V (2018). On the pharmacokinetics of two inhaled budesonide/formoterol combinations in asthma patients using modeling approaches. Pulmonary pharmacology & therapeutics 48 168–178. DOI:10.1016/j.pupt.2017.12.002 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29223508